The latest trading day saw McKesson (MCK) settling at $479.06, representing a -0.02% change from its previous close.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally.
In the latest trading session, McKesson (MCK) closed at $508.16, marking a -0.68% move from the previous day.
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson's recent sell-off offers a compelling opportunity, driven by its strong position in healthcare distribution and growing focus on AI and technology for sustainable growth. The company boasts solid revenue and EPS growth, supported by AI integration, expansion into high-demand sectors like GLP-1 and oncology, and a robust business model. Shareholder returns are enhanced by aggressive buyback plans, a 15% dividend hike, and a healthy balance sheet, despite a low 0.6% dividend yield.
McKesson (MCK) reachead $518.81 at the closing of the latest trading day, reflecting a +1.49% change compared to its last close.
McKesson (MCK) concluded the recent trading session at $511.17, signifying a +0.14% move from its prior day's close.
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Nasdaq 100 closed lower by over 500 points during Friday's session. Investors, meanwhile, focused on some notable insider trades.
MCK announces the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to grow oncology and biopharma services.